vs
Organogenesis Holdings Inc.（ORGO）与RE/MAX Holdings, Inc.（RMAX）财务数据对比。点击上方公司名可切换其他公司
Organogenesis Holdings Inc.的季度营收约是RE/MAX Holdings, Inc.的3.2倍（$225.6M vs $71.1M），Organogenesis Holdings Inc.净利率更高（19.4% vs 2.0%，领先17.3%），Organogenesis Holdings Inc.同比增速更快（78.1% vs -1.8%），Organogenesis Holdings Inc.自由现金流更多（$34.8M vs $33.5M），过去两年Organogenesis Holdings Inc.的营收复合增速更高（43.2% vs -4.7%）
Organogenesis Holdings Inc.是一家领先的再生医学企业，专注于开发、生产用于伤口护理、外科修复、运动医学和皮肤病领域的先进治疗产品，主要服务美国及部分国际市场的医疗机构与患者，提供经临床验证的医疗解决方案。
RE/MAX是全球知名的房地产特许经营机构，业务遍布全球一百多个国家和地区，旗下拥有数千家门店，总计超过十万名房产经纪人，在国际房产中介领域拥有极高的品牌知名度与市场影响力。
ORGO vs RMAX — 直观对比
营收规模更大
ORGO
是对方的3.2倍
$71.1M
营收增速更快
ORGO
高出80.0%
-1.8%
净利率更高
ORGO
高出17.3%
2.0%
自由现金流更多
ORGO
多$1.3M
$33.5M
两年增速更快
ORGO
近两年复合增速
-4.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $225.6M | $71.1M |
| 净利润 | $43.7M | $1.4M |
| 毛利率 | — | — |
| 营业利润率 | 28.1% | 13.1% |
| 净利率 | 19.4% | 2.0% |
| 营收同比 | 78.1% | -1.8% |
| 净利润同比 | 469.5% | -75.2% |
| 每股收益（稀释后） | $0.31 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ORGORMAX
| Q4 25 | $225.6M | $71.1M | ||
| Q3 25 | $150.9M | $73.2M | ||
| Q2 25 | $101.0M | $72.8M | ||
| Q1 25 | $86.7M | $74.5M | ||
| Q4 24 | $126.7M | $72.5M | ||
| Q3 24 | $115.2M | $78.5M | ||
| Q2 24 | $130.2M | $78.5M | ||
| Q1 24 | $110.0M | $78.3M |
净利润ORGORMAX
| Q4 25 | $43.7M | $1.4M | ||
| Q3 25 | $21.6M | $4.0M | ||
| Q2 25 | $-9.4M | $4.7M | ||
| Q1 25 | $-18.8M | $-2.0M | ||
| Q4 24 | $7.7M | $5.8M | ||
| Q3 24 | $12.3M | $966.0K | ||
| Q2 24 | $-17.0M | $3.7M | ||
| Q1 24 | $-2.1M | $-3.4M |
毛利率ORGORMAX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 72.6% | — | ||
| Q4 24 | 75.5% | — | ||
| Q3 24 | 76.7% | — | ||
| Q2 24 | 77.6% | — | ||
| Q1 24 | 73.9% | — |
营业利润率ORGORMAX
| Q4 25 | 28.1% | 13.1% | ||
| Q3 25 | 13.7% | 25.0% | ||
| Q2 25 | -12.5% | 19.3% | ||
| Q1 25 | -30.9% | 7.2% | ||
| Q4 24 | 8.1% | 5.9% | ||
| Q3 24 | 5.4% | 19.4% | ||
| Q2 24 | -10.7% | 20.6% | ||
| Q1 24 | -3.5% | 5.8% |
净利率ORGORMAX
| Q4 25 | 19.4% | 2.0% | ||
| Q3 25 | 14.3% | 5.4% | ||
| Q2 25 | -9.3% | 6.4% | ||
| Q1 25 | -21.7% | -2.6% | ||
| Q4 24 | 6.1% | 8.0% | ||
| Q3 24 | 10.7% | 1.2% | ||
| Q2 24 | -13.1% | 4.7% | ||
| Q1 24 | -1.9% | -4.3% |
每股收益（稀释后）ORGORMAX
| Q4 25 | $0.31 | — | ||
| Q3 25 | $0.11 | — | ||
| Q2 25 | $-0.10 | — | ||
| Q1 25 | $-0.17 | — | ||
| Q4 24 | $0.05 | — | ||
| Q3 24 | $0.09 | — | ||
| Q2 24 | $-0.13 | — | ||
| Q1 24 | $-0.02 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $93.7M | $118.7M |
| 总债务越低越好 | — | $432.2M |
| 股东权益账面价值 | $300.1M | $452.4M |
| 总资产 | $598.7M | $582.5M |
| 负债/权益比越低杠杆越低 | — | 0.96× |
8季度趋势，按日历期对齐
现金及短期投资ORGORMAX
| Q4 25 | $93.7M | $118.7M | ||
| Q3 25 | $63.7M | $107.5M | ||
| Q2 25 | $73.1M | $94.3M | ||
| Q1 25 | $110.0M | $89.1M | ||
| Q4 24 | $135.6M | $96.6M | ||
| Q3 24 | $94.3M | $83.8M | ||
| Q2 24 | $89.9M | $66.1M | ||
| Q1 24 | $88.6M | $82.1M |
总债务ORGORMAX
| Q4 25 | — | $432.2M | ||
| Q3 25 | — | $433.3M | ||
| Q2 25 | — | $434.4M | ||
| Q1 25 | — | $435.3M | ||
| Q4 24 | — | $436.2M | ||
| Q3 24 | $62.3M | $437.2M | ||
| Q2 24 | $63.8M | $438.1M | ||
| Q1 24 | $65.2M | $439.0M |
股东权益ORGORMAX
| Q4 25 | $300.1M | $452.4M | ||
| Q3 25 | $255.1M | $448.1M | ||
| Q2 25 | $233.2M | $442.4M | ||
| Q1 25 | $242.9M | $433.5M | ||
| Q4 24 | $262.9M | $429.5M | ||
| Q3 24 | $278.5M | $423.1M | ||
| Q2 24 | $263.5M | $418.4M | ||
| Q1 24 | $278.0M | $412.0M |
总资产ORGORMAX
| Q4 25 | $598.7M | $582.5M | ||
| Q3 25 | $509.8M | $582.2M | ||
| Q2 25 | $461.1M | $574.8M | ||
| Q1 25 | $467.4M | $571.4M | ||
| Q4 24 | $497.9M | $581.6M | ||
| Q3 24 | $446.3M | $578.6M | ||
| Q2 24 | $443.2M | $571.4M | ||
| Q1 24 | $458.5M | $566.7M |
负债/权益比ORGORMAX
| Q4 25 | — | 0.96× | ||
| Q3 25 | — | 0.97× | ||
| Q2 25 | — | 0.98× | ||
| Q1 25 | — | 1.00× | ||
| Q4 24 | — | 1.02× | ||
| Q3 24 | 0.22× | 1.03× | ||
| Q2 24 | 0.24× | 1.05× | ||
| Q1 24 | 0.23× | 1.07× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $39.4M | $40.9M |
| 自由现金流经营现金流 - 资本支出 | $34.8M | $33.5M |
| 自由现金流率自由现金流/营收 | 15.4% | 47.1% |
| 资本支出强度资本支出/营收 | 2.1% | 10.4% |
| 现金转化率经营现金流/净利润 | 0.90× | 28.39× |
| 过去12个月自由现金流最近4个季度 | $-24.5M | $56.8M |
8季度趋势，按日历期对齐
经营现金流ORGORMAX
| Q4 25 | $39.4M | $40.9M | ||
| Q3 25 | $3.1M | $17.7M | ||
| Q2 25 | $-32.9M | $4.6M | ||
| Q1 25 | $-19.9M | $5.7M | ||
| Q4 24 | $10.9M | $59.7M | ||
| Q3 24 | $8.7M | $17.6M | ||
| Q2 24 | $4.7M | $15.9M | ||
| Q1 24 | $-10.2M | $9.4M |
自由现金流ORGORMAX
| Q4 25 | $34.8M | $33.5M | ||
| Q3 25 | $844.0K | $16.4M | ||
| Q2 25 | $-36.5M | $2.9M | ||
| Q1 25 | $-23.6M | $4.0M | ||
| Q4 24 | $7.6M | $53.0M | ||
| Q3 24 | $6.1M | $16.3M | ||
| Q2 24 | $2.9M | $14.0M | ||
| Q1 24 | $-12.4M | $6.8M |
自由现金流率ORGORMAX
| Q4 25 | 15.4% | 47.1% | ||
| Q3 25 | 0.6% | 22.4% | ||
| Q2 25 | -36.1% | 4.0% | ||
| Q1 25 | -27.2% | 5.3% | ||
| Q4 24 | 6.0% | 73.2% | ||
| Q3 24 | 5.3% | 20.8% | ||
| Q2 24 | 2.2% | 17.8% | ||
| Q1 24 | -11.3% | 8.6% |
资本支出强度ORGORMAX
| Q4 25 | 2.1% | 10.4% | ||
| Q3 25 | 1.5% | 1.8% | ||
| Q2 25 | 3.6% | 2.2% | ||
| Q1 25 | 4.2% | 2.3% | ||
| Q4 24 | 2.7% | 9.1% | ||
| Q3 24 | 2.2% | 1.7% | ||
| Q2 24 | 1.4% | 2.4% | ||
| Q1 24 | 2.0% | 3.3% |
现金转化率ORGORMAX
| Q4 25 | 0.90× | 28.39× | ||
| Q3 25 | 0.14× | 4.45× | ||
| Q2 25 | — | 0.97× | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.43× | 10.28× | ||
| Q3 24 | 0.71× | 18.22× | ||
| Q2 24 | — | 4.29× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ORGO
暂无分部数据
RMAX
| Franchising Segment | $50.1M | 70% |
| Broker Fees | $13.9M | 20% |
| Annual Dues | $7.4M | 10% |
